The system provides a comprehensive solution for routine, as well as complex AFib ablations. Credit: Magic mine / Shutterstock.

Johnson & Johnson MedTech has received the US Food and Drug Administration (FDA) approval for its VARIPULSE Platform to treat drug-refractory paroxysmal atrial fibrillation (AFib).

This system is designed to deliver treatment using a single device that integrates Pulsed Field Ablation (PFA) therapy with advanced mapping capabilities.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The VARIPULSE Platform, which works in conjunction with the CARTO 3 Electro-anatomical Mapping System, enhances the safety and accuracy of ablation procedures by providing precise energy delivery and real-time catheter positioning visualisation.

It also enables minimal- to zero-fluoro workflow through its integration with an intracardiac echocardiography (ICE) ultrasound portfolio, offering imaging in real time.

Electrophysiologists can gain confidence in the treatment delivered through tissue proximity indication and lesion tagging.

The platform also allows for a single transseptal zero exchange workflow, making procedures efficient and predictable.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It provides a comprehensive solution for routine as well as complex AFib ablations.

Johnson & Johnson MedTech Electrophysiology president Jasmina Brooks said: “With this approval, we are excited to bring the VARIPULSE Platform to electrophysiologists and patients in the US, where AFib impacts nearly eight million people.

“As the only PFA platform uniquely designed for seamless integration with the CARTO 3 System, we are confident that this eagerly awaited platform will be a valuable tool for physicians in performing safe, effective and efficient AFib procedures with an intuitive and reproducible workflow, and minimal-to-no fluoroscopy.”

The FDA’s approval is backed by data from the admIRE prospective, multi-centre, non-randomised study.

Among 291 patients treated across 30 US healthcare centres, acute procedural success was achieved in 100% of cases, including 98% with first-pass isolation per vein.

Additionally, 85% reached peak primary effectiveness with minimal adverse events reported at only 2.9% while 25% of procedures were conducted without fluoroscopy.

Earlier this month, Johnson & Johnson MedTech concluded subject enrolment for the pilot phase of the OMNY-AF study of the investigational OMNYPULSE Platform for treating symptomatic paroxysmal AFib in Australia and the US.